The nation of Zimbabwe has turned down a major American health deal worth 367 million US dollars (272 million pounds) over five years because of Washington's request for confidential biological samples.
This move was revealed after a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa felt the deal was "skewed".
A government spokesperson has since stated that the United States was demanding access to biological samples for scientific study and profit while refused to share the resulting advantages from future treatments.
"We will now turn to the challenging and unfortunate task of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for continued talks to reach a deal agreeable to both sides so the country's critical HIV treatment initiative can continue.
Broader Implications
Zimbabwe's decision comes after a similar case in Kenya, where a court suspended a similar health funding agreement following concerns were raised about the security of citizens' health data.
Since resuming office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump claimed its spending was "wasteful" and his government was seeking government-to-government deals to boost transparency and responsibility.
Based on reports, Sixteen African countries have to date agreed to similar health pacts, constituting more than $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership would have delivered significant advantages for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Our nation was requested to surrender its biological resources and data over an extended period, without any corresponding assurance of access to any scientific breakthroughs – like new medicines or tests – that might be developed from that provided information," his statement read.
"Put simply, our country would provide the raw materials for medical research without any certainty that the end products would be available to our population should a new health crisis emerge."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the global health body and its push of one-on-one deals were disrupting frameworks previously established via the international organization.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to deal with potential pandemics.
"This mechanism is designed to ensure that when a country provides its samples, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to develop them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to ongoing dialogue with our American counterparts on how future collaboration could be structured in a way that honours the independence and interests of both nations."
Medical Community Response
Medical experts expressed it understood the government's concerns, but suggested that talks must proceed since much of the country's Aids initiatives relied on foreign aid.
"In cases where technical issues exist, such as those involving information security or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," it commented.
The halted deal highlights the complex tensions between receiving much-needed foreign assistance and safeguarding national sovereignty in an ever more data-driven world.